Verismo's SynKIR-310 Posts 80% ORR With No CRS or ICANS at ASH
Image
PHILADELPHIA – – November 04, 2026 -- Verismo Therapeutics' CD19-targeted KIR-CAR T therapy SynKIR-310 produced an 80% objective response rate (4 of 5 evaluable patients) in relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), with no cytokine release syndrome (CRS) or neurotoxicity (ICANS) of any grade. The data come from the first two dose cohorts of the Phase 1 CELESTIAL-301 trial (NCT06544265). The company will present updated results as an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting.
SynKIR-310 delivers 60% complete response rate and no dose-limiting toxicities in early cohorts
Across dose cohorts 1 and 2, the complete response rate was 60%. Median duration of response in complete responders has not been reached, and one patient remained in complete response at the 12-month assessment.